Factors influencing malignant mesothelioma survival: a retrospective review of the National Mesothelioma Virtual Bank cohort

Abstract

Background: Malignant mesothelioma (MM) is a rare but deadly malignancy with about 3,000 new cases being diagnosed each year in the US. Very few studies have been performed to analyze factors associated with mesothelioma survival, especially for peritoneal presentation. The overarching aim of this study is to examine survival of the cohort of patients with malignant mesothelioma enrolled in the National Mesothelioma Virtual Bank (NMVB). Methods: 888 cases of pleural and peritoneal mesothelioma cases were selected from the NMVB database, which houses over 1400 cases that were diagnosed from 1990 to 2017. Kaplan Meier’s method was performed for survival analysis. The association between prognostic factors and survival was estimated using Cox Hazard Regression method and using R software for analysis. Results: The median overall survival (OS) rate of all MM patients, including pleural and peritoneal mesothelioma cases is 15 months (14 months for pleural and 31 months for peritoneal). Significant prognostic factors associated with improved survival of malignant mesothelioma cases in this NMVB cohort were below the age of 45, female gender, epithelioid histological subtype, stage I, peritoneal occurrence, and had treatment that consisted of combining surgical therapy with chemotherapy. Combined surgical and chemotherapy treatment was associated with improved survival of 23 months in comparison to single line therapies. Conclusions: There has not been improvement in the overall survival for patients with malignant mesothelioma over many years with current available treatment options. Our findings show that combined surgical and chemotherapy treatment is associated with improved survival compared to local therapy alone.

The use of a next-generation sequencing-derived machine-learning risk-prediction model (OncoCast-MPM) for malignant pleural mesothelioma: a retrospective study

“…22 In modern analyses, many of these factors have been reconfirmed 6,23,24 and other factors have been identified. [25][26][27][28][29][30][31] Unfortunately, the existing indices are unable to integrate clinical characteristics, pathological features, and molecular profiling, and are also unable to generate patientlevel prognostication.…”

Workshop summary: Potential usefulness and feasibility of a US National Mesothelioma Registry

“…The NMVB was founded in 2006 as a resource for basic and clinical translational researchers. [35][36][37][38][39][40] Funded by the National Institute for Occupational Safety and Health (NIOSH), the NMVB currently contains data and biospecimens (tumor tissue, blood products, and control samples) from over 1600 patients with pleural and peritoneal mesothelioma as well as controls. The five collaborating academic health centers maintain their own specimens but share the deidentified data centrally, an approach that serves to control costs.…”

Malignant pleural mesothelioma nodules remodel their surroundings to vascularize and grow

“…Malignant pleural mesothelioma (MPM) is an extremely aggressive asbestos-related neoplasm originating from the pleural mesothelium (1,2). It is usually diagnosed at an advanced stage, and is characterized by poor prognosis and resistance to conventional chemotherapies (3). Surgery may be appropriate only at the early stage of the disease.…”